Litcius/Paper detail

FLT3-selective PROTAC: Enhanced safety and increased synergy with Venetoclax in FLT3-ITD mutated acute myeloid leukemia

Yuxin Tan, Lilan Xin, Qian Wang, Rong Xu, Xiqin Tong, Guopeng Chen, Linlu Ma, Fuwei Yang, Hongqiang Jiang, Nan Zhang, Jinxian Wu, Xinqi Li, Xinyi Guo, Chao Wang, Hai‐Bing Zhou, Fuling Zhou

2024Cancer Letters23 citationsDOI

Topics & Concepts

Myeloid leukemiaVenetoclaxToxicityCancer researchMedicineFms-Like Tyrosine Kinase 3PharmacologyLeukemiaProteasomeChemistryImmunologyInternal medicineMutationBiochemistryChronic lymphocytic leukemiaGeneProtein Degradation and InhibitorsMultiple Myeloma Research and TreatmentsUbiquitin and proteasome pathways
FLT3-selective PROTAC: Enhanced safety and increased synergy with Venetoclax in FLT3-ITD mutated acute myeloid leukemia | Litcius